期刊文献+

^68Ga-PSMA-617的制备及microPET显像研究 被引量:5

Preparation of ^68Ga-PSMA-617 and its microPET imaging in BGC-823 cell bearing mice
原文传递
导出
摘要 目的制备68Ga-PSMA-617探针,并进行放射性药物质量控制。用microPET研究该探针在正常鼠和PSMA(+)的荷人胃癌肿瘤(BGC-823)裸鼠体内的代谢情况。方法以0.05 mol/L HCl淋洗^68Ge-68Ga发生器得到68GaCl3,与DKFZ-PSMA-617试剂盒于85 ℃下反应5 min。用HPLC分析68Ga-PSMA-617的标记率以及在生理盐水和HSA体系中的稳定性,并测定脂水分配系数和蛋白结合率,对正常雌性BALB/c小鼠和BGC-823荷瘤鼠进行68Ga-PSMA-617 microPET显像,并与18F-FDG microPET显像进行对比。结果68Ga-PSMA-617的标记率达97.9%,可不经纯化直接使用。标记物在生理盐水和质量分数5%的HSA体系中稳定性良好,放置80 min后放化纯分别为94.9%和81.0%。小鼠体内分布结果表明,标记物主要经肾脏代谢,BGC-823荷裸鼠肿瘤部位有较高的放射性摄取(T/NT为2.28),且显像效果优于18F-FDG。结论68Ga-PSMA-617的制备简便且标记率高,可靶向PSMA(+)肿瘤部位,显像效果优于18F-FDG,有望应用于PSMA高表达肿瘤的临床诊断。 Objective To prepare 68Ga-PSMA-617 and perform its microPET imaging on both normal BALB/c mice and BGC-823 (PSMA expression) tumor bearing mice. Methods ^68 GaCl3 was eluted from ^68Ge-^68Ga generator by 0.05 mol/L HCl, then added to the DKFZ-PSMA-617 and heated at 85 ℃ for 5 min. The labeling efficiency and in vitro stability of ^68Ga-PSMA-617 in sodium chloride solution and HSA were analyzed by radio-HPLC. Water partition coefficient and plasma protein binding rate were also evaluated. MicroPET imaging was performed in normal female BALB/c mice and human gastric tumor (BGC-823) bearing mice at 60 min post-injection of ^68Ga-PSMA-617. ^18F-FDG was also injected to BGC-823 tumor bearing mice to acquire mieroPET imaging for contrast. Results The labeling yield of ^68Ga-PSMA-617 was 97.9%, and it could be used directly without purification. ^68Ga-PSMA-617 showed good in vitro stability in sodium chloride solution and 5% HSA, the radiochemieal purities were 94.9% and 81.0% respectively at 80 min post-incubation. 68Ga-PSMA-617 was water-solubility substance, and it cleared mainly through the kidneys. MicroPET imaging showed that ^68Ga-PSMA-617 could be accumulated in tumor (T/NT = 2. 28), which was better than ^18F-FDG. Conclusions Preparation of ^68Ga-PSMA-617 is convenient and has a high labeling yield. It can specifically target to PSMA expression tumors and has a promising prospect in clinical application.
出处 《中华核医学与分子影像杂志》 北大核心 2017年第9期568-571,共4页 Chinese Journal of Nuclear Medicine and Molecular Imaging
基金 国家自然科学基金(81371592,81401467,81571705)
关键词 前列腺特异性膜抗原 同位素标记 镓放射性同位素 正电子发射断层显像术 肿瘤 小鼠 小鼠 Prostate-specific membrane antigen Isotope labeling Gallium radioisotopes Positron-emission tomography Neoplasms Mice Mice, nude
  • 相关文献

参考文献3

二级参考文献29

  • 1Ido, T.; Wan, C. N.; Casella, V.; Fowler, J. S.; Wolf, A. P.; Reivich, M.; Kuhl, D. E. J. Labelled Compd. Radiopharm. 1978, 14, 175. 被引量:1
  • 2Wahl, R. L. J. Nucl. Med. 1996, 37, 1038. 被引量:1
  • 3Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J. Chem. Rev. 2010, 110, 2858. 被引量:1
  • 4Gleason, G. I. Int. J. Appl. Radiat. Isot. 1960, 8, 90. 被引量:1
  • 5Gabriel, M.; Decristoforo, C.; Kendler, D.; Dobrozemsky, G.; Heute, D.; Uprimny, C.; Kovacs, P.; Guggenberg, E.; Bale, R.; Virgolini, I. J. J. Nucl. Med. 2007, 48, 508. 被引量:1
  • 6Weiner, R. E.; Thakur, M. L. Biodrugs 2005, 19, 145. 被引量:1
  • 7Roivainen, A.; Tolvanen, T.; Salomaki, S.; Lendvai, G.; Ve- likyan I.; Numminen, P.; Vailila, M.; Sipil~i, H.; BergstrOm, M.; H~irk6nen, P.; L6nnberg, H.; L~ngstr~m, B. J. Nucl. Med. 2004, 45, 347. 被引量:1
  • 8Lendvai, G.; Velikyan, I.; Bergstrom, M.; Estrada, S.; La- ryea, D.; Valila, M. Eur. J. Pharm. Sci. 2005, 26, 26. 被引量:1
  • 9Zhu, H.; Huang, L. L.; Zhang, Y. Q.; Xu, X. P.; Sun, Y. H.; Shen, Y. M..J. Biol. Inorg. Chem. 2010, 15, 591. 被引量:1
  • 10Gedye, R.; Smith, F.; Westaway, K.; Humera, A.; Baldisern, L.; Laberge, L.; Rousell, J. Tetrahedron Lett. 1986, 27, 279. 被引量:1

共引文献18

同被引文献32

引证文献5

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部